Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study in Patients With Type 2 Diabetes
NCT01408095 · Eli Lilly and Company · PHASE2 · withdrawn · last registry update 2011-08-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Trial terminated no patients were screened or enrolled” | – | Registry record, Eli Lilly and Company |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GCK within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2012-08-21Results posted on the registry: Merck Sharp & Dohme LLC, MK-0941 + Placebo (NCT00824616)
- 2012-07-23Results posted on the registry: Merck Sharp & Dohme LLC, MK-0941 20 mg + MK-0941 5 mg (NCT00830791)
- 2012-07-11Results posted on the registry: Merck Sharp & Dohme LLC, MK-0941 + Placebo (NCT00511472)
- 2012-07-11Results posted on the registry: Merck Sharp & Dohme LLC, MK-0941 + Comparator: Placebo (NCT00873821)
- 2012-06-26Results posted on the registry: Merck Sharp & Dohme LLC, MK0941 + Comparator: Placebo (NCT00511667)
- 2012-05-28Results posted on the registry: Merck Sharp & Dohme LLC, MK-0941 (NCT00912002)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision